Skip to main content
AmigoFish

Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau

From BioCentury This Week · · 30 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Roche’s $15 billion biobucks deal (https://www.biocentury.com/article/661232) with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfronts for early-stage assets (https://www.biocentury.com/article/660996). On the latest BioCentury This Week podcast, BioCentury’s analysts assess trends to watch ahead of Shanghai Life Sciences Week, including how new rules have curtailed China’s IIT pathway and a proposed export-control regime that could complicate cell and gene therapy and siRNA deals. The analysts also discuss Merck KGaA’s $1.3 billion takeout of Silence (https://www.biocentury.com/article/661219), Arrowhead’s brain-shuttle tau data (https://www.biocentury.com/article/661169) and the dose dilemma facing tau-lowering therapies, and whether a preclinical biotech like Isomorphic (https://www.biocentury.com/article/661176) Labs can justify a $40-50 billion valuation.

View full story: https://www.biocentury.com/article/661224

#ChinaBiotech #siRNA #BiotechMA #DrugDiscovery #DrugDevelopment

0:00 Introduction 1:13 China Trends 9:00 Roche-Hansoh Deal 13:11 Merck KGaA Buys Silence 15:38 Arrowhead's Brain Shuttle 23:40 Isomorphic Labs Valuation

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem